Advertisement
The real killer of our time?
Quick: what causes heart disease, diabetes and cancer? It may be inflammation.
The truth about HRT
So, is hormone replacement therapy a good idea, or not? Get some good news right here.
     TERMS     GET A DAILY HEALTH TIP  
  
MAKE HEALTH24 YOUR HOMEPAGE   
H24 NEWS MEDICAL SCHEMES DIET FITNESS NATURAL MAN WOMAN SEX PREGNANCY CHILD TEEN SUN
FOCUS CENTRES MEDS ORAL PET MIND GRAPHICS VIDEOS ANTI-AGEING WIN TOOLS EXPERTS TALK FIND


Health care systems
Misleading research common: editor
Last updated: 17 April 2008
Misleading research is often published in major medical journals and doctors are lending their names to it, the editor of the Journal of the American Medical Association said.

Doctors, regulators, publishers and others are all taking money, information and small presents from pharmaceutical companies and being influenced in the process, said Dr Catherine DeAngelis.

Advertisement
"It goes for all of us," DeAngelis, whose journal is influential nationally and globally, said in a telephone interview.

Her journal, commonly known as JAMA, published a paper accusing Merck and Co. of suppressing data that showed its now-withdrawn pain drug Vioxx was harming patients, and saying that academic researchers had lent credibility to the company's allegedly manipulated research by putting their names on the work.

Merck and the independent researchers have denied this and say the journal is mistaken in this case.

But DeAngelis said there is a "gigantic" problem of drug companies influencing doctors and patients. Her journal presents the Merck case as a specific example of one facet of the problem.

"We have given away our profession and we have got to take it back," she said.

Drug companies spend millions of dollars on promotional materials, from pens to prescription pads. They pay for doctors to travel to seminars, often in exotic places, to learn about drugs.

They set up elaborate booths at medical meetings and send articulate drug representatives and "detailers" to pay personal visits to doctors.

Careful watchdogs
"Physicians in private practice shouldn't even take a pen from anybody, let alone pizza lunches or whatever," DeAngelis said.

In addition, the companies fund many medical studies. Government funds are usually only used for the first stages of research - the rest is left to companies who conduct studies to seek licensing for various drugs. DeAngelis said there is no way around this.

But, she added, "The editors (of medical journals) have to be very, very careful watchdogs over what we publish."

The influence does not usually amount to outright bribery, DeAngelis added. "We just have to be more careful, all of us, and insist that we are not going to be hoodwinked by them, fooled by them," she said.

"The physician should learn from other physicians, not from some detail person," DeAngelis said.

Consumers Union agreed

"Pharmaceutical companies need to get out of the business of 'ghostwriting' articles for medical journals," Dr John Santa, a medical consultant to Consumers Union, said in a statement.

One of the studies in the journal shows that Merck researchers mostly wrote one of the studies alleged to have shown the higher risk of deaths, but later added the names of Alzheimer's experts Dr Leon Thal of the University of California, San Diego, and Steven Ferris of New York University.

Ferris denies his name was simply pasted onto the study and said he was involved in both the research and in writing the article. "I am livid about it," he said in a telephone interview.

Thal died in a plane crash in 2007, but was a prominent Alzheimer's expert who would have been able to catch any errant data showing a risk of deaths or stroke, Ferris added.

"We did participate in the study and we did participate in the process of producing the final manuscript," Ferris said. – (Maggie Fox/Reuters Health)
 
Print this article on
 Rate this article
Poor 1 2 3 4 5 Excellent

 JOBS
Senior Secretary
Gauteng - North/Sandton
Infrastructure Resource
Gauteng - Johannesburg
Management Accountant
R450,000-500,000 Per Annum Cost To Company
Gauteng - Johannesburg
Financial Manager
R350,000-400,000 Per Annum Cost To Company
Gauteng - Johannesburg
Financial and Project Accountant
R300,000-360,000 Per Annum Cost To Company
Gauteng - Johannesburg
Financial Accountant
R380,000-420,000 Per Annum Cost To Company
Gauteng - Johannesburg
SSIS Business Intelligence Specialists (SSIS; SSAS)
R350,000-500,000 Per Annum Cost To Company
Gauteng - North/Sandton
Financial Accountant
R350,000-450,000 Per Annum Cost To Company
Gauteng - South
 Today's top stories
  • ZIM: ANTHRAX OUTBREAK LOOMS
  • TRAFFIC CAN BE HEARTBREAKING
  • FRENCH NEED BIGGEST CONDOMS
  • FAST FOOD LINKED TO ALZHEIMER'S
  • GLOBAL PUSH IN AIDS FIGHT
  • CANCER TESTS AT HOME
  • TAC TO RETRENCH 20%
     
    Subscribe to...
    *Daily tip
    *Weekly tip
    Want to subscribe to our newsletters?
    Click here.
    *Stand a chance to win R1000 every month!

     
     
     
     
    Advertisement

     Sponsored links
     Health24 links

    Advertisement

     

    © Health24 2000-2008. All rights reserved
      
    We comply with the HONcode standard for trustworthy health
    information.
    Verify here.